Study guide
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies
Key Takeaways Explain This Topic AI
Stevens-Johnson syndrome involves epidermal detachment of less than 10% of body surface, overlap SJS/TEN 10% to 30%, and toxic epidermal necrolysis more than 30%.
SCORTEN uses 7 criteria (age 40 or over, malignancy, heart rate 120 or more, detachment over 10%, urea over 10 mmol/L, bicarbonate under 20 mmol/L, glucose over 14 mmol/L) to predict TEN mortality.
DRESS usually starts 2 to 8 weeks after starting the drug, with fever, facial oedema, rash, lymphadenopathy, eosinophilia, and organ involvement, most often of the liver.
Acute generalised exanthematous pustulosis usually begins within about 48 hours of the drug, often an aminopenicillin, with many small non-follicular sterile pustules and neutrophilia.
HLA-B 15:02 predicts carbamazepine-induced SJS/TEN in people of Southeast Asian ancestry, and HLA-B 58:01 predicts allopurinol-induced SCARs, especially in Han Chinese, Korean, and Thai people.
Last updated: September 2026
- 7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies
- How Delayed Drug Reactions Work
Immediate (IgE-mediated) reactions are covered in the type I allergy section. Delayed T-cell reactions follow the Pichler subclassification of type IV hypersensitivity:
- Type Main Effector Typical Reactions
- IVa Th1 cells, macrophages (IFN-gamma) Allergic contact dermatitis
- IVb Th2 cells, eosinophils (IL-4, IL-5) Maculopapular exanthem, DRESS
- IVc Cytotoxic CD8+ T cells (perforin, granzyme B, granulysin ) SJS/TEN , fixed drug eruption
- IVd T cells recruiting neutrophils (CXCL8/IL-8) AGEP
- Maculopapular Exanthem (MPE)
The most common drug eruption. Symmetric red macules and papules start on the trunk 4–14 days after starting a drug (antibiotics, anticonvulsants, allopurinol). It fades within 1–2 weeks of stopping. The classic amoxicillin rash in Epstein-Barr virus infection is usually not a true allergy. Red flags that suggest a SCAR are facial swelling, fever, mucosal lesions, blisters, skin pain, dusky or target lesions, pustules, and abnormal blood tests.
Fixed Drug Eruption (FDE)
One or a few round, dusky red-violet plaques, sometimes blistering, that recur at the same site each time the drug is taken. Lips, genitals, hands, and feet are common.
Culprits: NSAIDs, sulfonamides (co-trimoxazole), paracetamol, tetracyclines, barbiturates .
Heals with slate-grey post-inflammatory pigmentation . Generalised bullous FDE can mimic SJS/TEN.
Patch testing on the previously affected site can identify the drug.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN)
- Category Epidermal Detachment
- SJS Less than 10% of body surface
- SJS/TEN overlap 10–30%
- TEN More than 30%
Timing: usually 4–28 days after first exposure, after a fever-and-sore-throat prodrome.
Clinical: painful dusky macules and atypical flat targets , which become blisters and sheets of detachment ( positive Nikolsky sign ), with erosions of at least two mucosal sites (eyes, mouth, genitals).
High-risk drugs: allopurinol, carbamazepine, lamotrigine, phenytoin, phenobarbital, sulfonamides (co-trimoxazole), nevirapine, oxicam NSAIDs . Mycoplasma pneumoniae can cause a similar mucositis-predominant picture, especially in children.
Pharmacogenetics: HLA-B*15:02 and carbamazepine (Southeast Asian ancestry; screen before prescribing in these groups); HLA-B*58:01 and allopurinol (Han Chinese, Korean, Thai); HLA-A*31:01 and carbamazepine DRESS and MPE in Europeans and Japanese.
Histology: full-thickness epidermal necrosis with sparse dermal inflammation. A frozen section of the blister roof separates it quickly from staphylococcal scalded skin syndrome.
Causality: the ALDEN algorithm scores drug timing, presence at onset, rechallenge, and notoriety.
SCORTEN (calculate within 24 hours of admission)
- Criterion (1 point each)
- Age ≥ 40 years
- Malignancy present
- Heart rate ≥ 120 per minute
- Epidermal detachment > 10% of body surface on day 1
- Serum urea > 10 mmol/L
- Serum bicarbonate < 20 mmol/L
- Serum glucose > 14 mmol/L
Predicted mortality in the original validation: 0–1 points about 3%, 2 about 12%, 3 about 35%, 4 about 58%, 5 or more about 90% .
Management
Stop the suspected drug immediately. Earlier withdrawal of drugs with a short half-life improves survival.
Transfer to a burn unit or intensive care for extensive disease.
Supportive care: warm room, fluids, nutrition, analgesia, non-adherent dressings (leave detached epidermis in place as a biological dressing), infection surveillance without routine prophylactic antibiotics, and thromboprophylaxis.
Daily ophthalmology review, plus oral, genital, and urological care to prevent scarring.
Immunomodulation is debated. Ciclosporin, IVIG, systemic corticosteroids, and TNF-alpha inhibitors (etanercept) are used in different centres, and no option is universally proven.
Afterwards, give a written allergy record and avoid the drug and closely related drugs for life. Long-term complications include dry eye, visual loss, nail loss, and genital strictures.
DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)
Timing: 2–8 weeks after starting the drug, which is later than other drug reactions.
Features: fever, widespread rash, facial oedema , lymphadenopathy, eosinophilia , atypical lymphocytes, and organ involvement: liver (most common), kidney, lung, heart, pancreas, and thyroid.
Drugs: aromatic anticonvulsants (carbamazepine, phenytoin, lamotrigine), allopurinol , sulfonamides, dapsone, minocycline, vancomycin, and others.
Viral reactivation: HHV-6 , and also EBV, CMV, and HHV-7, often in sequence.
RegiSCAR score: fever, lymphadenopathy, eosinophilia, atypical lymphocytes, skin involvement, organ involvement, time to resolution, and exclusion of other causes. < 2 no case, 2–3 possible, 4–5 probable, > 5 definite .
Treatment: stop the drug. Use potent topical steroids for mild disease without significant organ involvement, and systemic corticosteroids (for example prednisolone 0.5–1 mg/kg/day) tapered slowly over weeks to months when organs are involved. Ciclosporin is an option. Relapse is common if the taper is fast.
Late sequelae: autoimmune thyroiditis, type 1 diabetes, and other autoimmune disease months later.
Acute Generalised Exanthematous Pustulosis (AGEP)
Timing: rapid, usually within 48 hours (often within a day for antibiotics).
Clinical: fever, and many small non-follicular sterile pustules on red, oedematous skin, starting in the face and flexures . There is neutrophilia , and mild organ involvement is possible.
Drugs: aminopenicillins , pristinamycin, hydroxychloroquine (longer latency), diltiazem, terbinafine, and others.
Histology: subcorneal or intraepidermal spongiform pustules, papillary oedema, and sometimes eosinophils.
Course: resolves within about 2 weeks with superficial desquamation. Treat by stopping the drug and applying topical steroids.
Differential: generalised pustular psoriasis (longer course, psoriasis history).
Testing After Recovery
For delayed reactions, patch tests (useful in DRESS, AGEP, FDE on the affected site, and MPE), delayed-reading intradermal tests , and the lymphocyte transformation test can help identify the culprit. Drug provocation is contraindicated after SJS/TEN or DRESS.
Other Dermatological Emergencies
Emergency Key Features Immediate Action
Erythroderma Over 90% of body surface red and scaling; causes: eczema, psoriasis, drugs, cutaneous T-cell lymphoma (Sézary syndrome) , PRP, idiopathic Admit if unwell; fluids, warmth, emollients; biopsies, blood film and Sézary cell count; stop likely drugs; treat the cause
Eczema herpeticum Monomorphic punched-out erosions in atopic skin, fever Aciclovir (IV if unwell or periocular); eye review
Staphylococcal scalded skin syndrome (SSSS) Mainly young children; tender erythema, superficial (subcorneal) peeling , crusting around the mouth, no mucosal involvement ; exfoliative toxins A and B cleave desmoglein 1 IV anti-staphylococcal antibiotic (flucloxacillin), fluids, pain relief
Purpura fulminans Rapidly spreading purpura and skin necrosis with DIC, often meningococcal sepsis or protein C deficiency Emergency sepsis care, antibiotics, protein C replacement where indicated